Reported 2–3-years overall survival in IDH-mutant AML ranges between 51 and 89% in the literature; discrepancies are thought to be related to differences in cohort age, but some authors also argue that different specific IDH mutations may carry varied prognostic implications (3, 44, 45, 47, 54, 56, 57). The gene discussed is IDH1; the disease is acute myeloid leukemia.